At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 307 enrolled
Drug / intervention
Omiganandrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase 3 Open-Label Extension Study to Evaluate the Long-Term Safety of Omiganan Topical Gel in Subjects With Rosacea
In Brief
A Phase 3 clinical trial evaluating Omiganan for Rosacea. Completed, enrolled 307 participants across 28 sites in 8 countries.
Detailed Summary
This study evaluates the long-term safety of once-daily application of Omiganan topical gel in subjects with severe papulopustular rosacea.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsRosacea
CountriesAustralia, Canada, France, Netherlands, New Zealand, Sweden, United Kingdom, United States
Collaborators--
Timeline
Phase 3CompletedFinished
20162017201820192020202120222023202420252026
Enrollment StartOct 2015
First PostedOct 2015
Primary CompletionJul 2017
Study CompletionFeb 2018
TodayJul 2026
First PostedOct 15, 2015
Enrollment StartOct 1, 2015
Primary CompletionJul 14, 2017
Study CompletionFeb 8, 2018
TodayJul 2, 2026
Enrollment to primary: 1.8 yearsPosted 10.7 years ago
Interventions
Omiganandrug
Topical gel